Suggested recent literature

Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.

These articles are not part of the database yet. Each one is a suggestion. The AI judged it from the title and abstract only and can be wrong. A curator reads the full paper, and only then is it added to CancerImmunoDB. A column on this page shows the curators' decision as soon as there is one.

How the list is made

  1. Search. For every year from 2021 to 2026, PubMed is searched for primary research on cancer drugs together with immune terms, and the 100 best matches of each year are taken. Every PubMed ID comes from PubMed itself, never from the AI.
  2. AI screening. Google Gemini reads each title and abstract and says whether the study tests a named anticancer drug and measures its effect on the immune system, the same scope as the database. In a first check, it marked 33 of 40 articles that curators had already accepted as likely relevant (and 1 as uncertain), and it rejected all 20 unrelated cancer articles.
  3. Curator check. Curators read each suggested paper in full and decide. Accepted papers are entered into the database with their doses, techniques and immune terms.

Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.

574articles screened
360likely relevant
11uncertain
203not relevant
0checked by a curator
0accepted into the database
YearScreenedLikely relevant
20269961
202510081
20249872
20239245
202210052
20218549

Browse the suggestions

Reset Download the full list (CSV)

360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).

PMIDYearArticleDrugsStudy typeCancer typeIn the databaseCurator status
40513067 2026 Anti-angiogenic therapy combined with immune checkpoint blockade mediates CCR7 + CD8 + T-cell entry into HCC through high endothelial venules. Hepatology (Baltimore, Md.) Likely relevant The study evaluates anti-angiogenic therapy combined with immune checkpoint blockade in patients and orthotopic mouse liver tumor models, measuring HEV formation and T-cell infiltration. anti-angiogenic drugs; immune checkpoint blockade Mixed hepatocellular carcinoma anti-angiogenic drugs 0/0/0; immune checkpoint blockade 0/1/0 Awaiting curator check
40983502 2026 Alleviated T cell exhaustion and SLC1A3-mediated stroma-remodelling dictate chemoimmunotherapy efficacy in oesophageal squamous cell carcinoma. Gut Likely relevant Examines the combination of chemotherapy and anti-PD-1 in patients and murine models, measuring effects on CD8+ T cells and immune checkpoints. anti-programmed cell death protein-1 (PD-1) Mixed oesophageal squamous cell carcinoma anti-programmed cell death protein-1 (PD-1) 0/0/0 Awaiting curator check
41092615 2026 PD-L1 nanobody-engineered bacterial outer membrane vesicles delivering cuproptosis micelles for potentiated cancer immunotherapy. Biomaterials advances Likely relevant The study tests engineered nanoplatforms delivering elesclomol and immune checkpoint blockade in a mouse xenograft model and evaluates antitumor immune responses like CD8+ T cell infiltration. elesclomol; PD-L1 nanobody-engineered bacterial outer membrane vesicles; immune checkpoint inhibitors Animal triple-negative breast cancer elesclomol 0/0/0; PD-L1 nanobody-engineered bacterial outer membrane vesicles 0/0/0; immune checkpoint inhibitors 0/0/0 Awaiting curator check
41133967 2026 Sequential Tumor Microenvironment Reprogramming by Nanoplatform Potentiates Sonodynamic-Chemodynamic Therapy and Immune Checkpoint Blockade in Breast Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) Likely relevant The study experimentally tests a nanoplatform combining sonodynamic-chemodynamic therapy agents and a PD-L1 antibody in murine breast cancer models, measuring effects on effector T cell infiltration and systemic immune responses. manganese dioxide; calcium peroxide; chlorin e6; PD-L1 antibody Animal breast cancer manganese dioxide 0/0/0; calcium peroxide 0/0/0; chlorin e6 0/0/0; PD-L1 antibody 0/1/0 Awaiting curator check
41255280 2026 Combined Photothermal and mTOR-Targeted Therapy Overcomes Immune Evasion and Enhances Checkpoint Blockade Efficacy in Metastatic Triple-Negative Breast Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) Likely relevant The study tests a gold nanocomposite delivering photothermal and mTOR-targeted therapy (ASPPR∩A) combined with PD-1 blockade in cell lines and murine models, measuring immunogenic cell death, MHC-I presentation, and T-cell infiltration. ASPPR∩A; PD-1 blockade Mixed triple-negative breast cancer ASPPR∩A 0/0/0; PD-1 blockade 0/0/0 Awaiting curator check
41372408 2026 Agonists for cytosolic bacterial receptor ALPK1 induce antitumour immunity. Nature Likely relevant Experimentally tests ALPK1 agonists (ADP-Hep and UDSP-Hep) alone and with checkpoint inhibitors in mice, measuring various immune readouts including CD8+ T cell and dendritic cell activation. UDSP-Hep; ADP-Hep; checkpoint inhibitors Animal unspecified tumour UDSP-Hep 0/0/0; ADP-Hep 0/0/0; checkpoint inhibitors 0/0/0 Awaiting curator check
41469103 2026 P53-Armed Oncolytic Virotherapy Promotes the Efficacy of PD1 Blockade in Murine Osteosarcoma Tumors. Anticancer research Likely relevant The study tests oncolytic adenoviruses (OBP-301, OBP-702) and anti-PD1 in human and murine osteosarcoma cell lines and orthotopic mouse models, measuring immunogenic cell death markers and PD-L1/PD-L2 expression. anti-PD1; OBP-301; OBP-702 Mixed osteosarcoma anti-PD1 1/1/0; OBP-301 0/0/0; OBP-702 0/0/0 Awaiting curator check
41484455 2026 Pseudomonas aeruginosa induces tumor pyroptosis and immune activation to enhance checkpoint blockade in colorectal cancer. Cancer immunology, immunotherapy : CII Likely relevant The study tests P. aeruginosa and anti-PD-L1 antibody in vitro and in vivo, and measures immunogenic cell death, cytokine secretion, dendritic cell maturation, and CD8+ T cell infiltration. anti-PD-L1 antibody; Pseudomonas aeruginosa Mixed colorectal cancer anti-PD-L1 antibody 0/1/0; Pseudomonas aeruginosa 0/0/0 Awaiting curator check
41485690 2026 Gu-Jin-Xiao-Ji Decoction potentiates anti-PD-1 immunotherapy in lung cancer by inhibiting the PI3K/AKT/NF-κB/PD-L1 axis. Fitoterapia Likely relevant The study experimentally tests Gu-Jin-Xiao-Ji Decoction and a PD-1 inhibitor in mice and measures immune cell infiltration and cytokine levels. Gu-Jin-Xiao-Ji Decoction; PD-1 inhibitor Animal lung cancer Gu-Jin-Xiao-Ji Decoction 0/0/0; PD-1 inhibitor 0/0/0 Awaiting curator check
41491256 2026 Engineering bispecific exosome activators of T cells to target immune checkpoint inhibitor-resistant metastatic melanoma. Nature biotechnology Likely relevant The study tests bispecific exosome activators (BEAT) targeting PD-L1 and Wnt7b in melanoma mouse models and measures CD8+ T cell recruitment and activation. PD-1 inhibitor; anti-PD-L1; anti-Wnt7b Animal Melanoma PD-1 inhibitor 0/0/0; anti-PD-L1 0/15/0; anti-Wnt7b 0/0/0 Awaiting curator check
41501177 2026 SLC2A1+ tumour-associated macrophages spatially control CD8+ T cell function and drive resistance to immunotherapy in non-small-cell lung cancer. Nature cell biology Likely relevant Tests SLC2A1 genetic deletion/inhibition and alpha-PD-L1 in murine tumor models, measuring CD8+ T cell distribution and effector function. alpha-PD-L1; SLC2A1 inhibitor Animal non-small-cell lung cancer alpha-PD-L1 0/0/0; SLC2A1 inhibitor 0/0/0 Awaiting curator check
41528176 2026 131I-Labeled Dual Immune Checkpoint Inhibitors for Tumor Microenvironment Improvement To Enhance Antitumor Efficacy. Molecular pharmaceutics Likely relevant Experimentally tests a radiolabeled bispecific antibody in tumor-bearing mice and reports effects on CD8+ T cell infiltration, immunogenic cell death, and neutrophil activity. 131I-labeled cadonilimab; AK104 Animal non-small-cell lung cancer 131I-labeled cadonilimab 0/0/0; AK104 0/0/0 Awaiting curator check
41538362 2026 EGFR activation disrupts immunotherapy response via SHP2-mediated suppression of tumor-intrinsic response to IFN-γ. The Journal of clinical investigation Likely relevant The study experimentally tests SHP2 inhibition and immune checkpoint blockade in cancer models and investigates their effects on IFN-g responsiveness and T cell infiltration. immune checkpoint blockade; SHP2 inhibitor Mixed lung cancer immune checkpoint blockade 0/1/0; SHP2 inhibitor 0/0/0 Awaiting curator check
41580015 2026 Copper ionophores drive divergent responses to immune checkpoint inhibition across colorectal tumor models. Cancer letters Likely relevant Evaluates copper ionophores and PD-1 blockade in syngeneic colorectal cancer models and measures immune cell infiltration and calreticulin exposure. diethyldithiocarbamate; clioquinol; programmed cell death protein 1 (PD-1) blockade Animal colorectal cancer diethyldithiocarbamate 0/0/0; clioquinol 0/0/0; programmed cell death protein 1 (PD-1) blockade 0/0/0 Awaiting curator check
41591489 2026 Decorin facilitates T cell-mediated antitumor immunity and augments the efficacy of anti-PD1 immunotherapy. Cancer immunology, immunotherapy : CII Likely relevant The study experimentally tests Decorin overexpression in combination with an anti-PD1 antibody in mouse tumor models and measures CD8+ T cell infiltration and cytokine production. anti-PD1 antibody Animal cancer anti-PD1 antibody 0/0/0 Awaiting curator check
41612693 2026 Tumor cell AMPK activation enhances NK cell anti-tumor immunity and synergizes with PD-L1 blockade therapy. Molecular therapy : the journal of the American Society of Gene Therapy Likely relevant The study tests pharmacological/genetic modulators and PD-L1 checkpoint blockade in mice, assessing NK cell-mediated killing and immune-related gene signatures. PD-1 / PD-L1 pathway inhibitors; AMPK activators/inhibitors Animal cancer (general / unspecified in title) PD-1 / PD-L1 pathway inhibitors 0/0/0; AMPK activators/inhibitors 0/0/0 Awaiting curator check
41622807 2026 Potentiating Chemo-Immunotherapy via a Programmable Nanocapsule-Hydrogel Platform for Sequential Tumor Microenvironment Remodeling. Advanced materials (Deerfield Beach, Fla.) Likely relevant The study evaluates a delivery platform combining oxaliplatin and anti-PD-L1 in a murine breast tumor model, assessing immunogenic stress and T cell persistence. oxaliplatin; anti-PD-L1 Animal breast cancer oxaliplatin 12/5/2; anti-PD-L1 0/15/0 Awaiting curator check
41653296 2026 Digital spatial profiling reveals additive effects of triple therapy on tumor microenvironment: anti-PD-L1, anti-VEGF, and PARP inhibition in mouse models. Cancer immunology, immunotherapy : CII Likely relevant The study tests anti-PD-L1, anti-VEGF, and PARP inhibitors in mouse models and measures immune readouts including CD8+ Granzyme B+ cell infiltration and HEV formation. anti-PD-L1; anti-VEGF; PARP inhibitor; PARPi Animal ovarian cancer anti-PD-L1 0/15/0; anti-VEGF 0/0/0; PARP inhibitor 0/0/0; PARPi 0/0/0 Awaiting curator check
41663641 2026 Immune checkpoint inhibition increases antigen-specific T cell response in head and neck cancer. Scientific reports Likely relevant The study tests immune checkpoint inhibitors such as anti-PD-1 in mixed lymphocyte-peptide cultures with head and neck cancer cell lines and measures antigen-specific T cell responses. anti-PD-1; LAG-3; TIM-3 Cell line Head and neck cancer anti-PD-1 14/36/0; LAG-3 0/0/0; TIM-3 0/0/0 Awaiting curator check
41666678 2026 PD-L1-targeted photodynamic therapy orchestrates checkpoint blockade and immunogenic cell death for synergistic cancer immunotherapy. Redox biology Likely relevant The study tests a Photodegradation-Targeting Chimera combining verteporfin in mouse models and measures adaptive antitumor immunity and immunogenic cell death. verteporfin; PPA-VPF Animal unspecified tumor models verteporfin 0/0/0; PPA-VPF 0/0/0 Awaiting curator check
41667239 2026 KRAS-driven protein disulfide isomerase family A member 6 expression suppresses PRKR-like endoplasmic reticulum kinase-mediated immunogenic cell death to desensitise pancreatic ductal adenocarcinoma to immune checkpoint blockers. Gut Likely relevant The study tests the PDIA6 inhibitor PACMA31 in mouse models and measures CD8+ T cells and immunogenic cell death. PACMA31; immune checkpoint blockers (ICBs) Animal pancreatic ductal adenocarcinoma PACMA31 0/0/0; immune checkpoint blockers (ICBs) 0/0/0 Awaiting curator check
41671386 2026 SAICAR Drives T Regulatory Cell Differentiation and FOXP3 Maintenance to Promote Immunotherapy Resistance. Cancer research Likely relevant The study experimentally tests anti-PD-1 and 6-mercaptopurine in human tumors and mouse models and measures effects on Treg differentiation, FOXP3, and effector T-cell function. anti-PD-1; 6-mercaptopurine Mixed cancer anti-PD-1 14/36/0; 6-mercaptopurine 0/0/0 Awaiting curator check
41677856 2026 Stoking an anti-liver cancer immune response with cryoablation plus an intratumoral TLR9 agonist and dual checkpoint inhibitors. Cancer immunology, immunotherapy : CII Likely relevant The study tests cryoablation combined with CpG and dual checkpoint inhibitors in mice and measures immune cell profiles and cytokine levels. anti-PD-1; anti-CTLA-4; CpG Animal hepatocellular carcinoma anti-PD-1 14/36/0; anti-CTLA-4 1/10/7; CpG 0/1/0 Awaiting curator check
41723880 2026 Reprogramming tumour-associated macrophages in breast cancer via si-FOXM1-loaded lipid nanoparticles enhances immune checkpoint inhibitor efficacy. British journal of pharmacology Likely relevant The study tests lipid nanoparticles loaded with si-FOXM1 in vitro and in vivo xenograft models and measures their effect on reprogramming tumor-associated macrophages to the M1 phenotype. si-FOXM1-loaded lipid nanoparticles Mixed breast cancer si-FOXM1-loaded lipid nanoparticles 0/0/0 Awaiting curator check
41734997 2026 Serotonin transporter SERT: a novel immune checkpoint for CD8+ T cell antitumor therapy. Journal for immunotherapy of cancer Likely relevant Tests selective serotonin reuptake inhibitors (SSRIs) and anti-PD-1 therapy in mouse models and human xenografts and measures their effects on CD8+ T cell antitumor responses. selective serotonin reuptake inhibitors; SSRIs; anti-PD-1 therapy Mixed unspecified cancer selective serotonin reuptake inhibitors 0/0/0; SSRIs 0/0/0; anti-PD-1 therapy 0/0/0 Awaiting curator check
Page 1 of 15 Next →